About Tesamorelin - Visceral Fat Reduction Peptide

Tesamorelin is a growth hormone-releasing hormone (GHRH) that stimulates your pituitary gland to produce more of your body's natural growth hormone. It is especially famous for targeting stubborn visceral fat (deep abdominal belly fat) while supporting lean muscle and recovery.

WHAT THE RESEARCH SHOWS

Research on Tesamorelin, a potent Growth Hormone-Releasing Hormone (GHRH) analogue, is unique because it specifically targets stubborn, metabolically active fat while boosting natural growth hormone.
Here is what clinical studies show: Visceral Fat Reduction: It is the only peptide FDA-approved (under the brand name Egrifta*) specifically shown to dramatically reduce deep visceral adipose tissue (VAT) the dangerous fat wrapped around internal organs without causing loss of lean muscle.
* Natural GH & IGF-1 Release: By binding to pituitary receptors, it stimulates your body's own pulsatile release of human growth hormone and elevates systemic IGF-1 levels, avoiding the severe side effects and pituitary shutdown associated with direct exogenous HGH.
* Cognitive Function: Groundbreaking research (notably clinical trials funded by the NIH) demonstrated that Tesamorelin significantly improved executive function, working memory, and cognitive processing in adults with mild cognitive impairment.
* Cardiometabolic & Lipid Profiles: Studies show significant decreases in circulating triglycerides, visceral liver fat, and non-HDL cholesterol, improving overall cardiovascular markers.
For body composition and lean muscle, Tesamorelin is frequently paired with a GHRP like in the Tesamorelin + Ipamorelin combo to hit both the GHRH and secretagogue pathways simultaneously. If the primary focus is lean mass and budget value, the classic CJC-1295 + Ipamorelin combo is typically the top recommendation. The Tesamorelin + Ipamorelin combo is the ultimate stack for hitting both (to torch deep visceral belly fat, or more for muscle building and anti-aging) Tesamorelin specifically torches deep visceral fat while Ipamorelin triggers an amplified natural growth hormone pulse to build lean tissue and accelerate recovery. If your main priority shifts toward pure muscle growth and budget value, the CJC-1295 + Ipamorelin combo is also a top-tier daily standard.

STUDIES

• FDA approval (2010). It’s approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy (abnormal fat build-up linked to HIV and its treatment). It’s the only FDA-approved therapy for that condition.
• Main Phase 3 trials (Falutz 2010, pooled analysis). Two trials with 806 adults found 2 mg daily cut visceral fat (the deep fat around the organs) by about 15% compared with placebo over 26 weeks, which was highly significant. Fasting triglycerides also fell.
  • It targets visceral fat specifically and doesn’t cause general fat loss across the body.
  • Limb fat was largely unaffected, which matters for HIV patients who often lose fat from their arms and legs.
• Liver fat (2014, JAMA). In HIV patients with excess abdominal fat, tesamorelin reduced liver fat along with visceral fat.
  • The lead researcher also noted an improvement in a marker of liver inflammation (AST).

LINKS

• NATAP – Lancet HIV 2019 editorial and results
• HIV i-Base – Tesamorelin for NAFLD
• AJMC – Tesamorelin and NAFLD in HIV
• Medical Research – Grinspoon on JAMA 2014 trial
• Superpower – Tesamorelin guide
• Superpower – Tesamorelin (Egrifta SV)
• Superpower – Tesamorelin (fat distribution)

Lyophilised powder